Emerging signaling mediators in the anorexia-cachexia syndrome of cancer.
Trends Cancer
; 8(5): 397-403, 2022 05.
Article
en En
| MEDLINE
| ID: mdl-35190301
ABSTRACT
The cachexia syndrome in cancer is characterized by weight loss resulting from the combination of anorexia and atrophy of adipose and skeletal muscle. For decades, inflammatory circulatory factors have been identified to regulate wasting, but inhibitors of these factors have not yielded the same clinical benefit as in animal models. Therefore, additional mediators of cachexia likely regulate this syndrome, and such factors might be more suitable for targeted intervention. We highlight several anorexia-cachexia signaling mediators, including activin A, myostatin, GDF15, and lipocalin-2. We discuss current evidence that these factors associate with cachexia in cancer patients, and summarize translational efforts including essential early-phase clinical trials. We conclude with thoughts on targeted and personalized approaches for future anti-cachexia treatments.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Caquexia
/
Neoplasias
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Trends Cancer
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos